Previous close | 126.66 |
Open | 127.06 |
Bid | 130.60 x 100 |
Ask | 131.23 x 100 |
Day's range | 127.00 - 131.61 |
52-week range | 55.25 - 159.89 |
Volume | |
Avg. volume | 843,509 |
Market cap | 12.371B |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.80 |
Earnings date | 31 July 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 165.89 |
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 01, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2024.
CAMBRIDGE, Mass., April 30, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).